At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
DSXS topicaldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating DSXS topical for Atopic Dermatitis. Completed, enrolled 28 participants across 1 site.
Detailed Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedOct 2016
Primary CompletionApr 2017
Study CompletionDec 2017
TodayJul 2026
First PostedOct 13, 2016
Enrollment StartAug 1, 2016
Primary CompletionApr 14, 2017
Study CompletionDec 12, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago
Interventions
DSXS topicaldrug
topical treatment